John Wahren
Technik-/Wissenschafts-/F&E-Leiter bei Creative Peptides Sweden AB
Profil
John Wahren was the founder of Cebix, Inc. which was founded in 2008, where he held the title of Director & Chief Scientific Officer from 2010 to 2014.
He is currently employed as an Emeritus Professor-Clinical Physiology at Karolinska Institutet and as Chief Scientific Officer at Creative Peptides Sweden AB.
Dr. Wahren's former position was as a Professor at the University of Lausanne in 1984.
He obtained his doctorate degree from Karolinska Institutet.
Aktive Positionen von John Wahren
Unternehmen | Position | Beginn |
---|---|---|
Creative Peptides Sweden AB
Creative Peptides Sweden AB Pharmaceuticals: MajorHealth Technology Creative Peptides Sweden AB develops and manufactures drugs. The company discovers and develops biopharmaceutical drugs to treat complications of Type 1 diabetes. It was founded in 1996 and is headquartered in Stockholm, Sweden. | Technik-/Wissenschafts-/F&E-Leiter | - |
Karolinska Institutet | Corporate Officer/Principal | 24.06.2009 |
Ehemalige bekannte Positionen von John Wahren
Unternehmen | Position | Ende |
---|---|---|
University of Lausanne | Corporate Officer/Principal | 01.01.1984 |
Cebix, Inc.
Cebix, Inc. Pharmaceuticals: MajorHealth Technology Cebix, Inc. provided treatments for complications of diabetes. It developed Ersatta, a proprietary disease-modifying replacement peptide for the treatment of complications associated with diabetes, including diabetic peripheral neuropathy, autonomic neuropathy, nephropathy, and retinopathy. The company was founded by John Wahren and Lars G. Ekman in 2008 and was headquartered in San Diego, CA. | Gründer | - |
Ausbildung von John Wahren
Karolinska Institutet | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Private Unternehmen | 2 |
---|---|
Creative Peptides Sweden AB
Creative Peptides Sweden AB Pharmaceuticals: MajorHealth Technology Creative Peptides Sweden AB develops and manufactures drugs. The company discovers and develops biopharmaceutical drugs to treat complications of Type 1 diabetes. It was founded in 1996 and is headquartered in Stockholm, Sweden. | Health Technology |
Cebix, Inc.
Cebix, Inc. Pharmaceuticals: MajorHealth Technology Cebix, Inc. provided treatments for complications of diabetes. It developed Ersatta, a proprietary disease-modifying replacement peptide for the treatment of complications associated with diabetes, including diabetic peripheral neuropathy, autonomic neuropathy, nephropathy, and retinopathy. The company was founded by John Wahren and Lars G. Ekman in 2008 and was headquartered in San Diego, CA. | Health Technology |